Silvan Tuerkcan
Stock Analyst at Citizens
(4.48)
# 358
Out of 5,182 analysts
177
Total ratings
49.43%
Success rate
24.18%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Downgrades: Market Perform | n/a | $52.95 | - | 16 | Mar 26, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $50.99 | +68.66% | 17 | Dec 23, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $4.56 | +119.30% | 5 | Nov 20, 2025 | |
| ENGN enGene Therapeutics | Maintains: Market Outperform | $18 → $21 | $7.20 | +191.67% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $13.04 | +61.04% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $6.46 | +23.84% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $12.61 | +74.46% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $0.93 | +545.23% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $9.62 | +253.43% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $29.48 | +52.65% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $44.65 | +11.98% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $7.50 | +100.00% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.67 | +63.49% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $5.21 | +72.74% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $14.12 | +749.86% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.88 | +804.26% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $2.34 | +70.94% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $14.95 | +40.47% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.05 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.01 | +49.63% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $68.02 | +311.64% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $11.02 | +63.34% | 1 | Jan 26, 2023 |
Terns Pharmaceuticals
Mar 26, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $52.95
Upside: -
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $50.99
Upside: +68.66%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $4.56
Upside: +119.30%
enGene Therapeutics
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $7.20
Upside: +191.67%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $13.04
Upside: +61.04%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $6.46
Upside: +23.84%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $12.61
Upside: +74.46%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $0.93
Upside: +545.23%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $9.62
Upside: +253.43%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $29.48
Upside: +52.65%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $44.65
Upside: +11.98%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $7.50
Upside: +100.00%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.67
Upside: +63.49%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $5.21
Upside: +72.74%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $14.12
Upside: +749.86%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.88
Upside: +804.26%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.34
Upside: +70.94%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $14.95
Upside: +40.47%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.05
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $4.01
Upside: +49.63%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $68.02
Upside: +311.64%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $11.02
Upside: +63.34%